1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Imagin Medical Inc.

Imagin Medical Inc.

IME.CN
Imagin Medical Inc.CA flagCanadian Securities Exchange
0.02
CAD
- -
- -
162,451.00Market Cap
Imagin Medical Inc.
IME.CN
(Canadian Securities Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-17.08
-55.5
-35.77
-0.41
-8.78
-9.9
-2.54
-10.36
-1.3
-1.68
-0.63
-1.48
-0.64
-0.53
-1.27
-0.25
-0.31
Basic EPS, GAAP
-40.69
-23.68
-4.58
-6.95
-10.57
-6.99
-3.3
-3.38
-0.55
-1.15
-0.27
-0.86
-0.59
-0.5
-0.45
-0.34
-0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-70.14
-116.58
-143.55
-147.63
-142.56
-139.72
-140.2
-150.27
-1.3
-0.41
-0.59
0.59
-0.11
-0.4
-1.61
-1.65
-1.4
Book Value per Share
101.11
57.81
18.18
18.22
24.82
13.97
11.51
1.17
-0.28
-0.01
-0.26
1.09
0.28
-0.06
-1.29
-1.45
-1.19
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
5
7
8
9
10
11
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-8
-6
- -
-2
-2
- -
-2
- -
-2
-2
-8
-4
-4
-11
-2
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1
1
1
3
2
1
- -
- -
- -
-1
6
2
- -
-12
-15
-13
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
13
8
3
3
4
3
2
- -
- -
- -
-1
6
2
- -
-12
-13
-12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
122.27
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
ST Debt
13
14
11
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
3
3
2

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
15
15
13
Payables & Accruals
2
2
2
ST Debt
13
14
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
78,681.44%
390.44%
15.55%
Free Cash Flow
652.38%
112.67%
-16.9%
Net Income, GAAP
433.98%
90.82%
-78.28%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.06
-0.26
-0.05
- -
-1.27
2022
-0.14
-0.11
0.46
- -
-0.25
2023
- -
-0.08
0.2
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
ATS Medical, Inc. (ATSI)
Senseonics Holdings, Inc. (SENS)
PHC Holdings Corporation (6523.T)
Beijing Leadman Biochemistry Co.,Ltd. (300289.SZ)
NeuroMetrix, Inc. (NURO)
Vitrolife AB (publ) (VITR.ST)
Business
Imagin Medical Inc. (CSE: IME) develops innovative medical devices for visualizing and treating urologic cancers, including bladder and prostate cancer, through minimally invasive surgical technologies; its core products comprise the i/Blue Imaging System, which employs advanced proprietary optics, light sensors, and dual white-blue light imaging with fluorescent agents to enhance bladder cancer detection and reduce recurrence rates, and the enCAGE Coil Precision Ablation System, a bipolar radiofrequency-based probe that enables precise targeting of prostate cancer lesions via a coiled electrode creating a Faraday Effect to spare surrounding structures and minimize side effects such as erectile dysfunction and urinary incontinence. Founded in 1987 and headquartered in Vancouver, British Columbia, Canada, the company targets healthcare providers and urology institutions in North America with a focus on improving surgical outcomes and lowering healthcare costs. In 2022, Imagin acquired the enCAGE Coil technology from TROD Medical NV for US$2.5 million payable on milestones including FDA approvals and sales targets, supported by a US$7.25 million convertible note financing led by Rapha Capital BioVentures Fund I, LP and Bigger Capital; it also advanced the i/Blue Imaging System toward FDA submission via pre-production milestones and board changes appointing Kevin Slawin, M.D., as chairman.